INmune Bio Inc. Common stock (INMB) stock analysis and AI prediction
The company facts of INmune Bio Inc. Common stock, with its price and AI prediction for the next 10 market days in SharePreds.
Keep looking in SharePreds
You have looked at today's stocks on this website. SharePreds shows every stock's likelihood of rising, its chart and how its earlier predictions ended, with alerts on the ones you follow.
See all five apps
About INmune Bio Inc. Common stock
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
- Sector
- Healthcare
- Exchange
- NASDAQ
- Market value
- $32.5 million
- Size
- Micro cap
- Employees
- 21
- Headquarters
- BOCA RATON, FL
- Listed since
- Feb. 4, 2019
- Website
- inmunebio.com
More Healthcare stocks
Other micro cap stocks
Keep going
INMB questions
What is the AI prediction for INMB stock?
Each market day our model rates INmune Bio Inc. Common stock (INMB) Bullish, Neutral or Bearish for the next 10 market days. Predictions are indicative: they rest on price and volume data, and they can be wrong.
How often is the INMB prediction updated?
Each market day, Monday to Friday, except market holidays. The date of the prediction is shown beside it.
What do Bullish, Neutral and Bearish mean?
Bullish means the model sees a rise as likely over the next 10 market days, Bearish a fall, and Neutral no clear direction.
Where can I see the exact likelihood for INMB?
In the SharePreds app for iPhone and Android, with the stock's chart, alerts on it and how its earlier predictions ended.
Where can I see INMB options?
The INMB options page opens its calls and puts, with price, volume, implied volatility and the Greeks.